New Drug Approvals

Home » Posts tagged 'organic synthesis' (Page 9)

Tag Archives: organic synthesis

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,816,391 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Promising Antiviral Compounds Discovered


Scientists sifted through thousands of potentially efficacy compounds and managed to identify two promising candidates for the development of drugs against human adenovirus, a cause of ailments ranging from colds to gastrointestinal disorders to pink eye

Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have identified two promising candidates for the development of drugs against human adenovirus, a cause of ailments ranging from colds to gastrointestinal disorders to pink eye. A paper published in FEBS Letters, a journal of the Federation of European Biochemical Societies, describes how the researchers sifted through thousands of compounds to determine which might block the effects of a key viral enzyme they had previously studied in atomic-level detail.

http://www.dddmag.com/news/2013/07/promising-antiviral-compounds-discovered?et_cid=3348636&et_rid=523035093&type=cta

GSK tests ofatumumab in rare skin disorder


Ofatumumab

GlaxoSmithKline is to start a new Phase III study of ofatumumab as a treatment for pemphigus vulgaris, a rare autoimmune disorder of the skin, according to partner Genmab. The Danish biotech and the drug major are long-term partners on ofatumumab which is already marketed, as Arzerra, for chronic lymphocytic leukaemia.

http://www.pharmatimes.com/Article/13-07-04/GSK_tests_ofatumumab_in_rare_skin_disorder.aspx

Ofatumumab(trade name Arzerra, also known as HuMax-CD20) is a human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin’s lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia. This makes ofatumumab the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.

 

 

Orexo gets FDA OK for opioid dependence drug


Regulators in the USA have given the green light to Orexo of Sweden’s Zubsolv as a treatment for opioid addiction.

The US Food and Drug Administration has approved Zubsolv, a once-daily sublingual formulation of Reckitt Benckiser’s Suboxone (buprenorphine/naloxone) which currently dominates the market. It is indicated for use as maintenance treatment for people suffering from opioid dependence and should be used as part of a complete treatment plan to include counselling and psychosocial support

read all at

http://www.pharmatimes.com/Article/13-07-05/Orexo_gets_FDA_OK_for_opioid_dependence_drug.aspx

FDA clears Aurobindo’s Rizatriptan Benzoate orally disintegrating tablets


India-based Aurobindo Pharma has obtained final FDA approvals to manufacture and market Rizatriptan Benzoate orally disintegrating tablets (ODT) 5mg and 10mg (ANDA 203062)…

read more at

http://drugdiscovery.pharmaceutical-business-review.com/news/fda-clears-aurobindos-rizatriptan-benzoate-orally-disintegrating-tablets-030713

 

Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, the United StatesCanada andNew Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United KingdomItaly (as Rizaliv), Israel (as Rizalt), The NetherlandsCroatia and Spain (asMaxalt)

Anthrax Killer from the Sea


Anthrax Killer from the Sea

Unusual antibiotic from a marine actinomycete is effective against anthrax

Read more

http://www.chemistryviews.org/details/ezine/4972631/Anthrax_Killer_from_the_Sea.html

From Pharmacy to the Pub — A Bark Conquers the World: Part 3


The long road from the structure determination to the total synthesis of quinine is an exciting detective story

Read more

http://www.chemistryviews.org/details/ezine/4971211/From_Pharmacy_to_the_Pub__A_Bark_Conquers_the_World_Part_3.html

 

Sandoz launches generic metronidazole in the US


Sandoz  has launched metronidazole 1% topical gel, the first generic version of METROGEL® 1%.

read all at

http://www.pharmaintellect.com/2013/07/sandoz-launches-generic-metronidazole.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmainvest+%28PharmaInvest%29

 

Biosimilar drugs step up complexity, by Phillip Broadwith


The first ever generic monoclonal antibody therapies have been recommended for approval in Europe. The two biosimilar versions of infliximab (Johnson & Johnson’s Remicade) have passed assessment by the European Medicines Agency’s committee for medicinal products for human use, but will need to be fully approved by the European commission before they can be marketed.

Monoclonal antibodies are significantly larger and more complex than previously approved biosimilars, which include growth hormones and erythropoietin. Proving that they are functionally similar to the original drug is therefore complex. Both manufacturers, Celltrion and Hospira, had to complete human trials to prove that their generic infliximab products were as safe and effective as Remicade in treating autoimmune diseases.

read all at

http://www.rsc.org/chemistryworld/2013/07/biosimilar-approval-steps-complexity

Array Starts First Phase 3 Trial, Shifts to Late-Stage Development


HY-15202

 MEK162

(Synonyms  ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162)

MEK162 M.Wt: 441.23
MEK162 Formula: C17H15BrF2N4O3
MEK162 Storage: at -20℃ 2 years
MEK162 CAS No.: 606143-89-9

http://clinicaltrials.gov/ct2/show/NCT00959127

 

Array Starts First Phase 3 Trial, Shifts to Late-Stage Development
Xconomy
Array Biopharma said Tuesday it has received a $5 million milestone payment from Novartis for beginning Phase 3 testing of a drug it hopes can treat ovarian cancer. The milestone is just part of a larger transition for the Boulder, CO-based biopharmaceutical company.

read all at

http://www.xconomy.com/boulder-denver/2013/07/03/array-starts-first-phase-3-trial-shifts-to-late-stage-development/

FDA awards Activartis brain cancer drug Orphan Drug Designation


image02_700px_250px_01

Austrian biotech company Activartis has received Orphan Drug Designation for its cancer immunotherapy AV0113 from the US Food and Drug Administration.

The experimental vaccine will be fast-tracked for evaluation after it was shown to improve survival rates in people with malignant glioma, an advanced form of brain cancer in a phase II clinical trial earlier this year.

http://www.pharmaceutical-technology.com/news/newsfda-awards-activartis-brain-cancer-drug-orphan-drug-designation?WT.mc_id=DN_News